{"name":"Nano PharmaSolutions Australia","slug":"nano-pharmasolutions-australia","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQazlmeU9ZQm5HZnFNQ2gwZE8wMm51TGRmM2tfR25vZnpic3UtSmktWng5RG11cVMtZzFHczdxOU84amxRMEpfTnJ1dkNJUEx0RXZuQXAxMXRuVC1OMjdZTFJKanBtZ0FhZUZsOGNyWHF0Z29rZWJndl9JTkdqMUR3NXRab2ljX2w4SE9BcVA3ZGtHNHlidGtHNnhGSTRrOXp2bmVqbWdnRldWUFphVkMzMGtTRGZQbFE3N21iczl2ZVV3anJTVWNfaUs4aDJWdmowMU40?oc=5","date":"2025-09-19","type":"trial","source":"BioPharma APAC","summary":"Mikart and Nano PharmaSolutions Report Positive Phase 1 Data for NT-301 in Parkinson’s Disease - BioPharma APAC","headline":"Mikart and Nano PharmaSolutions Report Positive Phase 1 Data for NT-301 in Parkinson’s Disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxNRXpnTWJQMWhDMWRQUXE0bmdmUGxBaFoyU2trTFFLclFMRnpTcmttc1R1ZFNKRHlHSUc1N3JSaXM1cHRtRUtWSkRidnRmbnVQU21rZU1jdHU5Qi02UWJtY0IyclM0ZC1BTDY2dFE0M0Y3VkdDZ1F2ZHlyUjlMTEk3N1R2cEpyY01kRkxKNUowMnpnak1PSjl2OTZ6bXJjZEtNMVlLX3JOMERjLXJfUFpSNXA1Rklwa3NHRE5rVFZuNFVVY2ttNGhCa0UwSGItSUx1ZVpZWDEzemdMQW85Y25BQlpSTW5HTDBTcmlWNk94d3p1RkdqcUZnSTEySmlKMnlJZDlyQk1BZWhGRlhTSVp4Rk9rYTJOcWhxY1RwZHdsbVNpYjc3VTVUNXBhQm4?oc=5","date":"2025-09-18","type":"trial","source":"PR Newswire","summary":"Mikart and Nano PharmaSolutions Announce Positive Interim Data from NT-301 Phase 1 Trial and Expansion of NanoTransformer® Manufacturing Capabilities - PR Newswire","headline":"Mikart and Nano PharmaSolutions Announce Positive Interim Data from NT-301 Phase 1 Trial and Expansion of NanoTransforme","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}